References
- Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20 (2): 303–315.
- Barry AL, Fuchs PC, Brown S. In vitro activity of dap-tomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45: 1919-1922.
- Jones RN, Barry AL. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother 1991; 31: 625–29.
- King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001; 48: 219–223.
- Rybak MJ, Hershberger E, Moldovan T, Grutz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quin-upristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062–1066.
- Silva M, Jacobus NV, Gorbach SL. In vitro activity of LY146032 against Gram-positive bacteria. Diag Microbiol Infect Dis 1988; 9: 79–85.
- Snydman DR, Jacobus NV, McDermott LA et al. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother 2000; 44: 3447–3450.
- Tally FP, Zeckel M, Wasilewski MG, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investigat Drugs. 1999; 8 (8): 1223–1238.
- Thorne GM, Adler J. Daptomycin: A novel lipopeptide antibiotic. Clin Microbiol Newslett 2002; 24 (5): 33–39.
- Wise R, Andrews JM, Ashby JP. The activity of dapto-mycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 200148: 563-567.
- National Committee for Clinical Laboratory Standards (renamed Clinical and Laboratory Standards Institute, 2005). Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically. M7-A6, Approved standard 6th ed. NCCLS 2000 Wayne, PA, USA.
- National Committee for Clinical Laboratory Standards (renamed National Institute for Clinical Laboratory Standards, 2005). Methods for determining bactericidal activity of antimi-crobial agents. M26-T, vol. 12, no. 19. NCCLS 1992. Wayne, PA, USA.
- Odds FC. Synergy, antagonism, and what the checker-board puts between them. [Editorial] J Antimicrob Agents Chemother 2003; 52:1.
- Eliopolus GM, Moellering RC Jr. Antimicrobial combinations. In: Lorian, V., ed, Antibiotics In Laboratory Medicine, 4th ed. pp 330-396. Baltimore, Maryland: Williams and Wilkins, 1996.
- Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of I3-lactams, daptomycin, gentamicin, and glycopeptides against glycopep-tide-resistant enterococci. Antimicrob Agents Chemother 1991; 35: 92–98.
- Bingen E, Lambert-Zechovski N., Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, dap-tomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;.26: 619–26.
- Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 145032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 1993; 39: 302–310.
- Atkins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin and gentamicin alone and/or in combi-nation against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925–1929.